May 29, 2026

Award for Heidelberg Evolutionary Geneticist

Award for Heidelberg Evolutionary Geneticist

Henrik Kaessmann receives Ernst Schering Prize for fundamental contributions to understanding mammalian evolution

Henrik Kaessmann | © Tobias Schwerdt

Prof. Dr Henrik Kaessmann has been selected to receive the 2026 Ernst Schering Prize for his pioneering research into the evolutionary origins and genetic regulation of organ development and organ function. The award, which comes with 50,000 euros in prize money, is presented by the Schering Stiftung and recognizes outstanding scientific achievements in biological, medical or chemical basic research. With his team at the Center for Molecular Biology of Heidelberg University (ZMBH), Prof. Kaessmann investigates the molecular and cellular origins and evolution of vertebrate organs. His systematic, cross-species analyses include jawless vertebrates as well as birds, reptiles and mammals – including humans.

With his studies on the evolution of gene expression and the emergence of new genes, Henrik Kaessmann has fundamentally expanded our understanding of the development of vertebrate organs while pushing conceptual and methodological boundaries, according to the citation for the award to the Heidelberg evolutionary geneticist. In large-scale single-cell studies, Prof. Kaessmann and his team were able, for instance, to identify genetic changes that, over the course of evolution, contributed to the development of the unusually large and complex human brain or to human-specific adaptations in the liver. He has also succeeded in decoding the genetic mechanisms that underlie the evolution of sex chromosomes in mammals, birds and reptiles.

The foundation further states that Henrik Kaessmann’s research, at the interface of evolutionary biology, developmental genomics and molecular biology, combines basic research questions with direct medical relevance. By decoding how genes are activated and controlled in different cells and organs, he creates important frames of reference for biomedical research. His comparative datasets and analyses provide fundamental benchmarks and new starting points for research into a wide range of diseases, particularly those affecting the brain, liver and reproductive organs. Prof. Kaessmann and his team have also identified promising candidate genes that may be linked to disease risks or fertility.

Henrik Kaessmann studied biology at LMU Munich and Uppsala University in Sweden. In 2001, he earned his doctorate from Leipzig University with a dissertation completed at the Max Planck Institute for Evolutionary Anthropology. After a research stay at the University of Chicago in the USA, he moved in 2003 to the Center for Integrative Genomics at the University of Lausanne in Switzerland, where he ultimately served as full professor. In 2015 he accepted an appointment at Heidelberg University’s Faculty of Biosciences. Henrik Kaessmann has received numerous awards for his research, including three substantial grants from the European Research Council (ERC) as well as the Friedrich Miescher Award and the Cloëtta Prize. He is a member of the European Molecular Biology Organization and the German Academy of Sciences Leopoldina.

With its science award, the Schering Stiftung honors researchers worldwide each year whose basic research in biology, chemistry or medicine is pioneering. The award ceremony for the 2026 Ernst Schering Prize to Henrik Kaessmann will take place on 17 November at the Berlin-Brandenburg Academy of Sciences and Humanities in Berlin.

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp